Clinical Trial Update: Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating activated T cells expressing second- or third-generation CD19-directed CAR-T cells in advanced B-cell malignancies. The study is curren…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• CD19-directed CAR-T cell therapy (second/third generation) (CD19-directed CAR-T cell therapy)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Status: RECRUITING